Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 90.52 USD 3.66% Market Closed
Market Cap: 6.3B USD
Have any thoughts about
Lantheus Holdings Inc?
Write Note

Lantheus Holdings Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lantheus Holdings Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Lantheus Holdings Inc
NASDAQ:LNTH
Accrued Liabilities
$161.7m
CAGR 3-Years
52%
CAGR 5-Years
37%
CAGR 10-Years
17%
Haemonetics Corp
NYSE:HAE
Accrued Liabilities
$49.3m
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
-1%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Accrued Liabilities
$675m
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
7%
ICU Medical Inc
NASDAQ:ICUI
Accrued Liabilities
$297.8m
CAGR 3-Years
50%
CAGR 5-Years
20%
CAGR 10-Years
33%
Align Technology Inc
NASDAQ:ALGN
Accrued Liabilities
$574.6m
CAGR 3-Years
4%
CAGR 5-Years
15%
CAGR 10-Years
21%
Merit Medical Systems Inc
NASDAQ:MMSI
Accrued Liabilities
$138.7m
CAGR 3-Years
-3%
CAGR 5-Years
9%
CAGR 10-Years
16%
No Stocks Found

Lantheus Holdings Inc
Glance View

Market Cap
6.3B USD
Industry
Health Care

Lantheus Holdings Inc. is a dynamic healthcare company specializing in the development, manufacture, and commercialization of innovative diagnostic imaging agents, particularly in the field of nuclear medicine. Founded in 1956, the company has established a solid reputation for improving patient care through advanced diagnostics, helping healthcare providers make more informed decisions. Lantheus is perhaps best known for its flagship products, including nuclear imaging agents like Pylarify, used in the detection of prostate cancer. With a robust pipeline of novel radiopharmaceuticals in various stages of development, the company is strategically positioned to address unmet needs in diagnostics and therapeutics, thereby enhancing both patient outcomes and shareholder value. For investors, Lantheus represents a compelling opportunity, particularly as the demand for precision medicine continues to grow. With healthcare trends increasingly leaning towards personalized treatment, Lantheus is poised to grow through strategic partnerships, expanding market access, and leveraging new technologies. The company's commitment to innovation is underscored by its recent achievements and promising clinical trials, which have the potential to reshape the landscape of cancer diagnostics and treatment. As Lantheus Holdings continues to expand its portfolio and strengthen its market presence, investors can look forward to both solid financial performance and meaningful contributions to the evolving field of medical diagnostics.

LNTH Intrinsic Value
147.73 USD
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Lantheus Holdings Inc's Accrued Liabilities?
Accrued Liabilities
161.7m USD

Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Accrued Liabilities amounts to 161.7m USD.

What is Lantheus Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
17%

Over the last year, the Accrued Liabilities growth was 37%. The average annual Accrued Liabilities growth rates for Lantheus Holdings Inc have been 52% over the past three years , 37% over the past five years , and 17% over the past ten years .

Back to Top